Search

Scott Lloyd Tarriff

from Miami Beach, FL
Age ~65
Get Report
Also known as:
Scott L Tarriff, Scott L Tariff
Related to:
Beverly Jayne Anderson, 89Melvin R Anderson, 95Brian J Fallon, 65Ada Tarriff, 97Kevin Fallon, 30Marsha L Tarriff, 65Katherine T Fallon, 64Ryan S Fallon
Connected to:
Melody M Tarrillion, 73Joshua I Tarrington, 36Tina Tarring, 105Gregory P Tarris, 78Steve A Tarris, 88Bill A Tarro, 79Christine D Tarro, 32Dennis J Tarro, 65Chris J Tarrolly, 54Megan Tarrolly, 43

Scott Tarriff Phones & Addresses

  • Miami Beach, FL
  • 429 S Beach Rd, Hobe Sound, FL 33455
  • New York, NY
  • Aspen, CO
  • 28 Tudor Rose Ter, Mahwah, NJ 07430 (201) 512-0255 (201) 995-9246
  • 5 Surrey Ln, Mahwah, NJ 07430 (201) 995-9246
  • Jupiter, FL
  • State College, PA
  • Marianna, FL
  • Orange Pk, FL
  • Monroe Township, NJ
  • Palm Beach, FL
  • Belle Mead, NJ

Business Records

Name / Title
Company / Classification
Phones & Addresses
Scott L. Tarriff
President
Eagle Pharmaceuticals, Inc
Mfg Pharmaceutical Preparations
Woodcliff Lake, NJ 07677
50 Tice Blvd, Westwood, NJ 07677
470 Chestnut Rdg Rd, Westwood, NJ 07677
(201) 326-5300
Scott Tarriff
PHARMACEUTICAL RESOURCES, INC
1 Ram Rdg Rd, Spring Valley, NY 10977
1 Ram Rdg Rd, Spring Valley, NY 10977
Scott Tarriff
PAR PHARMACEUTICAL, INC
1 Ram Rdg Rd, Spring Valley, NY 10977
1 Ram Rdg Rd, Spring Valley, NY 10977
Scott Tarriff
Managing
Scott Tarriff, LLC
28 Tudor Rose Ter, Mahwah, NJ 07430

Publications

Us Patents

Method Of Treating Bendamustine-Responsive Conditions In Patients Requiring Reduced Volumes For Administration

View page
US Patent:
20130253026, Sep 26, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/838267
Inventors:
Scott L. Tarriff - Mahwah NJ, US
Assignee:
EAGLE PHARMACEUTICALS, INC. - Woodcliff Lake NJ
International Classification:
A61K 31/4184
US Classification:
514394
Abstract:
Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease.

Vial With Collar Label

View page
US Patent:
D676572, Feb 19, 2013
Filed:
Oct 3, 2011
Appl. No.:
29/403209
Inventors:
Scott L. Tarriff - Mahwah NJ, US
Assignee:
Eagle Pharmaceuticals, Inc. - Woodcliff NJ
International Classification:
2401
US Classification:
D24224, D9719

Method Of Treating Bendamustine-Responsive Conditions In Patients Requiring Reduced Volumes For Administration

View page
US Patent:
20150343061, Dec 3, 2015
Filed:
Aug 6, 2015
Appl. No.:
14/820291
Inventors:
- Woodcliff Lake NJ, US
Scott L. Tarriff - Mahwah NJ, US
International Classification:
A61K 47/10
A61K 47/02
A61K 47/20
A61K 31/4184
Abstract:
Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease.

Method Of Treating Bendamustine-Responsive Conditions In Patients Requiring Reduced Volumes For Administration

View page
US Patent:
20150080444, Mar 19, 2015
Filed:
Nov 26, 2014
Appl. No.:
14/554269
Inventors:
- Woodcliff Lake NJ, US
Scott L. Tarriff - Mahwah NJ, US
International Classification:
A61K 31/4184
A61K 47/20
A61K 47/02
A61K 47/10
A61K 9/00
US Classification:
514394
Abstract:
Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 100 ml or less intravenously over a period of about 30 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease.
Control profile
Scott Lloyd Tarriff from Miami Beach, FL, age ~65 Get Report